U.S. Consumer Finance Stock News

NYSE:PAGS
NYSE:PAGSDiversified Financial

Evaluating PagSeguro Digital (PAGS) Valuation As Earnings Growth Expectations Clash With Cut Analyst Estimates

Upcoming earnings and current sentiment Market attention is centering on PagSeguro Digital (PAGS) ahead of its upcoming quarterly results, with expectations for year-over-year growth in earnings and revenue, but recent estimate cuts are adding a layer of uncertainty for investors. See our latest analysis for PagSeguro Digital. PagSeguro Digital's share price has been choppy, with a 2.79% one day decline and a 7.92% 90 day share price return. The 1 year total shareholder return of 9.61%...
NYSE:MMS
NYSE:MMSProfessional Services

Has The Market Mispriced Maximus (MMS) After Its Recent 22.9% Year-To-Date Decline?

Wondering if Maximus stock is offering fair value or a potential bargain right now, especially after a tough stretch for returns. The share price last closed at US$66.66, with Maximus delivering a 1.6% return over the past week and 2.3% over the last month, but a 22.9% decline year to date and a 10.6% decline over the last year hint at changing sentiment. Recent coverage has focused on how Maximus fits into investors' long term portfolios and whether the current price reflects its...
NasdaqGS:LQDT
NasdaqGS:LQDTCommercial Services

Assessing Liquidity Services (LQDT) Valuation As Recent Share Price Momentum Draws Attention

Why Liquidity Services stock is back on investor radars Liquidity Services (LQDT) has caught investor attention after a period of solid share price momentum over the past month and past 3 months, prompting a closer look at its current valuation. See our latest analysis for Liquidity Services. While the 1 day share price return of Liquidity Services has recently dipped 2.61%, a 30 day share price return of 14.90% and 22.51% year to date, alongside a 3 year total shareholder return of 135.54%,...
NasdaqCM:NEO
NasdaqCM:NEOHealthcare

Is NeoGenomics’ Higher 2026 Revenue Outlook And Narrower Loss Profile Altering The Investment Case For NEO?

In late April 2026, NeoGenomics, Inc. raised its full‑year 2026 revenue guidance to US$797.0 million–US$803.0 million and reported first‑quarter sales of US$186.67 million with a narrower net loss of US$17.11 million compared with a year earlier. The combination of stronger quarterly performance and higher revenue expectations suggests the company’s oncology testing business is gaining traction, even as it remains loss‑making. We’ll now examine how NeoGenomics’ higher 2026 revenue outlook...
NYSE:RNR
NYSE:RNRInsurance

RenaissanceRe Chair Change And Renewed Buybacks Focus Attention On Capital Use

RenaissanceRe Holdings (NYSE:RNR) has appointed Henry Klehm III as Non-Executive Chair, succeeding the company’s long-serving board leader. The board also renewed its share repurchase program, authorizing up to $750 million of buybacks. These moves highlight changes in board oversight and capital allocation at a time when the stock trades around $300.84. RenaissanceRe Holdings comes into this leadership change with the stock at $300.84 and multi year share price gains, including 10.5% year...
NYSE:DNOW
NYSE:DNOWTrade Distributors

Is DNOW (DNOW) Worth Another Look After Its Recent Share Price Weakness

If you are wondering whether DNOW stock offers value at today’s price, the key question is how that price lines up with the company’s underlying fundamentals. The stock last closed at US$13.05, with returns of 6.3% over 30 days, a 3.3% decline over 7 days, a 2.3% decline year to date, and a 10.2% decline over 1 year. The 3 year and 5 year returns sit at 43.1% and 19.8% respectively. These mixed returns highlight that sentiment around DNOW can shift over different time frames. This often...
NYSE:KKR
NYSE:KKRCapital Markets

Is It Time To Reassess KKR (KKR) Around US$100 After Mixed Recent Returns

Wondering if KKR at around US$100 per share is starting to look like value or if the stock still prices in a lot of optimism? This article walks through that question with a clear focus on what you are paying versus what you are getting. KKR has recently seen a 10.6% return over the last 30 days, even as year to date returns sit at 22.2% in the red and the 1 year return is a 15.0% loss, on top of a very large 111.1% gain over 3 years and 90.0% over 5 years. These mixed returns come against a...
NYSE:DX
NYSE:DXMortgage REITs

Is Dynex Capital (DX) Pricing Look Attractive After Recent Share Price Swings?

If you are wondering whether Dynex Capital's current share price offers good value or carries more risk than reward, the starting point is to look closely at how it stacks up on valuation. The stock recently closed at US$13.32, with a 7 day return of 2.2% decline, a 30 day return of 5.0%, a year to date return of 5.4% decline, and a 1 year return of 25.5%, which gives you a mix of short term setbacks and longer term gains to weigh up. Recent coverage around Dynex Capital has focused on how...
NYSE:VOYG
NYSE:VOYGAerospace & Defense

How Voyager’s Raised 2026 Revenue Guidance and Record Backlog Could Shape Voyager Technologies (VOYG) Investors

In early May 2026, Voyager Technologies, Inc. reported first-quarter sales of US$35.25 million, a net loss of US$43.98 million, and raised its full-year 2026 revenue guidance to a range of US$230 million to US$255 million, supported by a record US$275 million backlog and new defense contracts. The company is also funding new technology development while actively seeking accretive acquisitions, aiming to enhance scale, margins and its overall position across missile defense and commercial...
NasdaqGS:ALRM
NasdaqGS:ALRMSoftware

Why Alarm.com (ALRM) Is Up 5.8% After Raising Guidance And Unveiling AI-Powered SaaS Push

In early May 2026, Alarm.com Holdings reported first-quarter revenue of US$265.19 million, up from US$238.82 million a year earlier, while GAAP net income eased to US$23.58 million and diluted earnings per share from continuing operations moved to US$0.47 from US$0.52. Alongside raising its full-year 2026 outlook, the company highlighted double-digit SaaS and license revenue growth, new AI-driven video analytics features, and a US$150 million share repurchase authorization, underscoring...
NYSE:DLB
NYSE:DLBSoftware

Is Dolby (DLB) Using Buybacks And Dividends To Quietly Redefine Its Premium Audio Strategy?

Dolby Laboratories, Inc. recently reported its second-quarter fiscal 2026 results, with revenue of US$395.63 million and net income of US$94.92 million, and issued third-quarter and full-year 2026 guidance alongside confirming a quarterly dividend of US$0.36 per share and progress on its long-running share repurchase program. An interesting detail is that since the buyback’s initiation in 2009, Dolby has retired over 54.33 million shares for about US$3.16 billion, materially shrinking its...
NYSE:BA
NYSE:BAAerospace & Defense

Is Boeing (BA) Offering Value After Safety Concerns And A Mixed Valuation Picture?

If you are wondering whether Boeing's current share price gives you good value, it helps to separate headline noise from what the numbers actually suggest about the stock. Boeing's stock most recently closed at US$231.03, with total returns of 0.9% over 7 days, 10.0% over 30 days, 1.4% year to date, 20.5% over 1 year, 14.5% over 3 years and 3.8% over 5 years. Recent attention on Boeing has focused on safety and quality issues across parts of its commercial aircraft business, with regulatory...
NasdaqGS:GRAB
NasdaqGS:GRABTransportation

Assessing Grab Holdings (GRAB) Valuation After Strong Q1 Earnings And AI Growth Updates

Why Grab’s Q1 earnings matter for shareholders Grab Holdings (GRAB) reported first quarter 2026 revenue of US$955 million and net income of US$136 million, both higher than a year earlier, with earnings surpassing analyst expectations and indicating improved operational efficiency. See our latest analysis for Grab Holdings. The Q1 beat and updates on AI products, autonomous rides and financial services come against a mixed share price backdrop, with a 6.5% 1 month share price return but a...
NYSE:STC
NYSE:STCInsurance

A Look At Stewart Information Services (STC) Valuation As Mixed Signals Emerge On Growth And P/E Ratios

Key recent performance and business mix Stewart Information Services (STC) has seen mixed share price moves recently, with a gain over the past month alongside a small decline over the past 3 months and year to date. The stock’s past year total return of 11.5% contrasts with a modest loss over the past 3 years. Over 5 years, the total return stands at 35.96%, giving investors a varied performance profile to assess. On the fundamentals side, the company reports annual revenue of US$3.10b and...
NasdaqGS:ROP
NasdaqGS:ROPSoftware

What Roper Technologies (ROP)'s AI-Fueled Outlook Hike and New Credit Line Means For Shareholders

In the past quarter, Roper Technologies reported Q1 2026 adjusted DEPS of US$5.16, 11.3% revenue growth, raised its full-year profit outlook, and arranged a US$3.50 billion revolving credit facility to support future acquisitions. A key takeaway is that AI-driven demand across Roper’s software portfolio is becoming a central earnings driver while the larger credit line enhances financial flexibility for further portfolio expansion. We’ll now examine how Roper’s raised profit outlook,...
NasdaqGS:ACAD
NasdaqGS:ACADBiotechs

A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Mixed Q1 2026 Results And EU Trofinetide Setback

ACADIA Pharmaceuticals (ACAD) is back in focus after first quarter 2026 results showed 10% year over year revenue growth to US$268.1 million, alongside weaker earnings, higher expenses, and a setback for trofinetide in Europe. See our latest analysis for ACADIA Pharmaceuticals. The mixed Q1 2026 update, together with the negative EU opinion on trofinetide and leadership changes in research and development, appears to be feeding into a share price that has struggled year to date despite a...
NasdaqGS:XERS
NasdaqGS:XERSPharmaceuticals

A Look At Xeris Biopharma Holdings (XERS) Valuation After Its Profit Turnaround And Guidance Hike

Xeris Biopharma Holdings (XERS) stock is in focus after the company reported a profitable first quarter of 2026 and raised its full year revenue guidance to US$380 million to US$390 million. See our latest analysis for Xeris Biopharma Holdings. The guidance hike and first quarter profit have come after a mixed period for the stock, with a 12.95% 1 month share price return and a 9.80% year to date share price decline. At the same time, 1 year and 3 year total shareholder returns of 28.49% and...
NasdaqGM:IESC
NasdaqGM:IESCConstruction

Is IES Holdings (IESC) Still Fairly Valued After Strong Q2 Earnings And Share Price Surge

IES Holdings (IESC) shares have been moving after the company reported second quarter 2026 earnings, with higher sales, net income, and earnings per share compared with the same period a year earlier. See our latest analysis for IES Holdings. The earnings release and the recent agreement to acquire Broadwind's Abilene facility have come alongside strong share price momentum, with a 30 day share price return of 38.13% and a 1 year total shareholder return of 165.60%. Multi year total...
NasdaqGS:SHC
NasdaqGS:SHCLife Sciences

A Look At Sotera Health (SHC) Valuation After Q1 2026 Results And CEO Transition

Sotera Health (SHC) just delivered a busy first quarter, pairing 10% year-over-year revenue growth and a move back to profitability with reaffirmed 2026 guidance and a planned CEO transition. See our latest analysis for Sotera Health. The share price is US$15.67 after a 7.04% 1 month share price return. However, the 90 day share price return of 11.72% and year to date share price return of 11.42% suggest recent momentum has cooled. Even so, the 1 year total shareholder return of 18.44% and 3...
NasdaqGS:TSLA
NasdaqGS:TSLAAuto

Tesla (TSLA) Is Up 7.9% After Record Semi Deal And AI Push - Has The Bull Case Changed?

In recent weeks, Tesla has reported a rebound in China-made EV sales, secured its largest-ever Semi truck order from WattEV worth about US$100 million, posted stronger quarterly earnings with margin recovery, and advanced major AI, robotaxi and chip initiatives including the Terafab semiconductor project in Texas. Taken together with the Model Y clearing new US safety evaluations and ongoing robotaxi pilots, these developments underscore Tesla’s push to reposition itself as a vertically...
NYSE:CRI
NYSE:CRILuxury

A Look At Carter's (CRI) Valuation After Its First Quarter Earnings Beat And Upgraded Guidance

Earnings beat and guidance reset the conversation for Carter's stock Carter's (CRI) stock is back in focus after first quarter 2026 results came in ahead of analyst expectations on both revenue and profit, along with Q2 and full year guidance that surprised positively. See our latest analysis for Carter's. At a share price of $35.75, Carter's has a year to date share price return of 7.68%, while the 1 year total shareholder return stands at 7.31%. This is set against a weaker 3 year and 5...
NasdaqGM:PAYO
NasdaqGM:PAYODiversified Financial

A Look At Payoneer Global (PAYO) Valuation After Recent Mixed Share Performance

Event context and recent share performance Payoneer Global (PAYO) has drawn attention after a period of mixed share performance, with the stock up about 4.1% over the past day and 5.2% over the past month, but showing a 20.1% decline over the past 3 months. See our latest analysis for Payoneer Global. That recent 1-day share price return of 4.1% and 30-day share price return of 5.2% sit against a weaker backdrop, with a 90-day share price return showing a 20.1% decline and a 1-year total...
NasdaqGS:DXCM
NasdaqGS:DXCMMedical Equipment

A Look At DexCom (DXCM) Valuation After Strong Q1 Growth And Upgraded Profitability Guidance

Why DexCom's latest earnings matter for investors DexCom (DXCM) just reported first quarter 2026 results, with revenue of US$1.192b and net income of US$199.5m, alongside higher margins and updated profitability guidance that put cash generation and product momentum in focus. See our latest analysis for DexCom. Despite the strong first quarter update and profitability guidance, DexCom's recent share price performance has been weak. The 90 day share price return shows a 12.95% decline and the...
NasdaqGS:NUVL
NasdaqGS:NUVLBiotechs

Assessing Nuvalent (NUVL) Valuation After NDA Milestones Guardant Alliance And Quarterly Loss

Nuvalent (NUVL) is in focus after a cluster of company updates, including first quarter earnings that showed a net loss of US$109.28 million and new detail on late stage oncology milestones. See our latest analysis for Nuvalent. At a share price of US$102.40, Nuvalent has seen mixed short term moves, with a 1 day share price return of 1.78% decline but a 1 year total shareholder return of 43.02%. This points to stronger momentum over a longer window as investors weigh the NDA progress,...